IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma

This study is testing a new type of immune cell therapy called IL1RAP-targeting CAR-T cell therapy for people with advanced liver cancer (hepatocellular carcinoma) that has stopped responding to or cannot be treated with standard therapies. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced liver cancer confirmed by biopsy or imaging - Your cancer cannot be surgically removed and has progressed after at least one standard treatment (such as targeted therapy or immunotherapy) - Your expected survival is at least 3 months **You may NOT be eligible if...** - You have another active cancer (other than early-stage skin cancers) - Your cancer has spread to the brain - You are pregnant or breastfeeding - The study doctor believes participation would not be appropriate for your health situation Talk to your doctor to see if this trial is right for you.